{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-23-009118","form_type":"8-K","ticker":null,"cik":"0001629205","company_name":"Innovation1 Biotech Inc.","filed_at":"2023-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.840117+00:00","generated_at":"2026-06-07T13:30:08.681653+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Innovation1 Biotech raises $150k via secured convertible notes and warrants","bullets":["Gross proceeds of $150,000 from $176,472 principal notes at 8% interest, mature Jan 6, 2025.","2,205,882 common stock purchase warrants issued at exercise price of $0.08 per share.","Notes convertible into common stock at $0.08 per share, with 4.99% beneficial ownership limit.","Transaction exempt from registration under Rule 506(b) of Securities Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-23-009118","json":"https://secwatch.observer/filing/0001477932-23-009118.json","markdown":"https://secwatch.observer/filing/0001477932-23-009118.md","text":"https://secwatch.observer/filing/0001477932-23-009118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1629205/000147793223009118/0001477932-23-009118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1629205/000147793223009118/ivbt_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:30:08.681653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e855ae1e2f4f6fb8261b127b543119be9a32626","claim":"Innovation1 Biotech Inc. incurred convertible notes of $176,472 with three lenders (the “Purchasers”) at 8% per annum maturing January 6, 2025.","evidence_excerpt":"On December 7, 2023, Innovation1 Biotech Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with three lenders (the “Purchasers”), pursuant to which the Company issued and sold the Purchasers Original Issue Discount Secured Convertible Promissory Notes in the principal amount of $176,472 (collectively, the “Notes”) for gross proceeds of $150,000.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1629205/000147793223009118/0001477932-23-009118-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$176,472"},{"label":"Counterparty","value":"three lenders (the “Purchasers”)"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"January 6, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"b0d175d57be84d46177ddaf3dd103f745e0d3119","claim":"Innovation1 Biotech Inc. entered into Securities Purchase Agreement with three lenders (the \"Purchasers\") valued at $176,472 (effective 2023-12-07).","evidence_excerpt":"On December 7, 2023, Innovation1 Biotech Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Agreement”) with three lenders (the “Purchasers”), pursuant to which the Company issued and sold the Purchasers Original Issue Discount Secured Convertible Promissory Notes in the principal amount of $176,472","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1629205/000147793223009118/0001477932-23-009118-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"three lenders (the \"Purchasers\")"},{"label":"Value","value":"$176,472"},{"label":"Effective","value":"2023-12-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}